SRRA - シエラ・オンコロジ― (Sierra Oncology Inc.) シエラ・オンコロジ―

 SRRAのチャート


 SRRAの企業情報

symbol SRRA
会社名 Sierra Oncology Inc (シエラ・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Sierra Oncology Inc. formerly ProNAi Therapeutics Inc. is a clinical-stage drug development company. The Company’s lead drug candidate SRA737 is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1) a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141 an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.   シエラ・オンコロジ―はカナダ医薬品メ―カ―。臨床段階で独自のDNA干渉技術(DNAi)により、がん治療薬の開発に従事する。主な薬剤候補は「PNT2258」で、アポト―シスとして知られる細胞死プロセスに関連し、過剰発現するがん遺伝子BCL2をタ―ゲットに開発する。薬剤は静脈点滴により体内へ取り込まれる。本社はバンク―バ―。   Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
本社所在地 2150 - 885 West Georgia Street Vancouver British Columbia V6C 3E8 CAN
代表者氏名 Donald R. Parfet ドナルドRパーフェット
代表者役職名 Independent Chairman of the Board
電話番号 +1 604-558-6536
設立年月日 37742
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 57人
url www.sierraoncology.com
nasdaq_url https://www.nasdaq.com/symbol/srra
adr_tso
EBITDA EBITDA(百万ドル) -45.49600
終値(lastsale) 1.659
時価総額(marketcap) 123336996.279
時価総額 時価総額(百万ドル) 131.58920
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 6.16420
当期純利益 当期純利益(百万ドル) -36.87900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sierra Oncology Inc revenues was not reported. Net loss increased 10% to $23.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.46 to -$0.35.

 SRRAのテクニカル分析


 SRRAのニュース

   Sierra Oncology to Present at Three September Investor Conferences  2021/09/07 11:00:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life
   Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  2021/09/03 20:05:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual
   Sierra Oncology accelerates planned filing of myelofibrosis candidate momelotinib  2021/08/09 12:08:29 Seeking Alpha
   Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding  2021/08/09 11:00:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data from the Phase 3 registration-enabling MOMENTUM study by February 2022, and assuming positive results, the company plans to file a New Drug Application with the U.S. Food &
   Sierra Oncology Bets $216M On AstraZeneca''s BET Inhibitor For Myelofibrosis  2021/08/06 12:06:55 Benzinga
Sierra Oncology Inc (NASDAQ: SRRA ) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN ) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153 in myelofibrosis patients in 1H of 2022. Under the agreement terms, Full story available on Benzinga.com
   Karyopharm Therapeutics (NASDAQ:KPTI) versus Sierra Oncology (NASDAQ:SRRA) Head-To-Head Contrast  2020/10/24 23:00:43 Daily Political
Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability. Insider & Institutional Ownership 95.9% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, […]
   Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) Critical Contrast  2020/10/22 20:14:46 US Banking News
Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Insider & Institutional Ownership 95.9% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, […]
   The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology  2020/02/11 12:23:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.
   Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead  2020/02/06 12:00:00 PR Newswire
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1,…
   Sierra Oncology : Shares Drop 12% Before Reverse Stock Split | MarketScreener  2020/01/22 18:08:02 MarketScreener
By Chris Wack Sierra Oncology shares dropped 12% to 34 cents after the company said its board of directors approved a reverse stock split of its shares at a ratio of 1-for-40, effective… | January 22, 2020

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シエラ・オンコロジ― SRRA Sierra Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)